ENTX

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

Entera Bio to Showcase EB613 at Upcoming Osteoporosis Webinar

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Entera Bio Ltd. will host a webinar on April 20, 2026, featuring its lead candidate EB613 for osteoporosis. The event aims to discuss treatment opportunities and advances in oral therapies, likely influencing investor sentiment and market activity based on clinical advancements and expert insights.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Entera to host KOL webinar on osteoporosis on April 20, 2026.</li><li>EB613 is Entera&#039;s lead candidate for osteoporosis, showing promising Phase 2 results.</li><li>Webinar includes discussions with top osteoporosis experts on treatment paradigms.</li><li>The FDA has received Entera&#039;s full Phase 3 protocol for EB613.</li><li>EB613 aims to be the first oral treatment option for osteoporosis.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>OPKO Health, Inc. (OPK)</strong>: Collaboration for developing oral therapies, potentially affecting market sentiments.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>This fits within Industry News, highlighting advances in osteoporosis treatment options and market dynamics surrounding Entera&#039;s innovative products.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Upcoming KOL webinar could significantly raise awareness and interest in EB613.</li><li>Positive Phase 2 results create a favorable backdrop for the Phase 3 clinical trial.</li><li>Expert endorsements at the webinar may enhance credibility for EB613.</li><li>Regulatory updates and insights shared during the webinar can influence investor sentiment.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>EB613 is a once-daily oral treatment for osteoporosis.</li><li>Phase 2 trial with 161 patients showed positive biomarker and BMD results.</li><li>FDA received Entera&#039;s Phase 3 protocol amendment in March 2026.</li><li>Webinar scheduled for April 20, 2026, at 11:00 AM ET.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investors should consider accumulating ENTX shares leading up to the webinar, expecting positive market response.</p>
  </section>
</section>


<article>
    <h2>Entera Bio to Host Key Opinion Leader Webinar on Osteoporosis Treatment and EB613</h2>
    <p>TEL AVIV, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/quote/ENTX">ENTX</a>), a pioneering company in the development of oral peptides, has announced a virtual Key Opinion Leader (KOL) webinar scheduled for Monday, April 20, 2026, at 11:00 AM Eastern Time. This event will focus on the current landscape of osteoporosis treatment and the potential for Entera's leading clinical candidate, EB613 (an oral PTH (1-34) tablet).</p>
    
    <section>
        <h3>Registration and Event Details</h3>
        <p>Participation in this important discussion requires registration. Interested parties can register <a href="https://events.zoom.us/ev/AjJwNRe2lJ20ip76GJ4k0Ee_SLHBTKEcb9Iabu7PDwVyGRBCzqr_~AqIJON0d6_lhurfYvEmThe3o4X3G0iFAy9zFmuBnQMCqifflBtC23k66Fg" target="_blank" rel="nofollow">here</a>. Participants are encouraged to join the webinar at least 10 minutes before the start time to ensure smooth access.</p>
    </section>

    <section>
        <h3>Insights from Industry Experts</h3>
        <p>The webinar will feature a roundtable discussion led by Entera's Chief Executive Officer, Miranda Toledano, alongside prominent key opinion leaders in the fields of osteoporosis treatment and women's health. Topics will include:</p>
        <ul>
            <li>The importance of women's bone health during and after menopause</li>
            <li>Current treatment paradigms in osteoporosis management</li>
            <li>Anabolic therapies in clinical practice</li>
            <li>The potential role of EB613 as the first oral anabolic treatment option</li>
        </ul>
        <p>The event will also include discussions with esteemed experts:</p>
        <ul>
            <li><strong>Dr. Felicia Cosman</strong>, Professor of Medicine at Columbia University, an authority in osteoporosis and anabolic therapies</li>
            <li><strong>Dr. Steven Goldstein</strong>, Professor of Obstetrics and Gynecology at NYU Grossman School of Medicine and former President of both the International and North American Menopause Societies</li>
        </ul>
    </section>

    <section>
        <h3>Webcast Information</h3>
        <p>The webinar will be broadcasted via a pre-recorded webcast at 11:00 AM ET. A replay will be available on Entera's website shortly after the event concludes. For access to the replay, please visit <a href="https://investors.enterabio.com/investor-calendar" target="_blank" rel="nofollow">this link</a>.</p>
    </section>

    <section>
        <h3>About EB613</h3>
        <p>EB613 is being developed as the first oral, once-daily anabolic tablet for the treatment of osteoporosis. A Phase 2, 6-month, 161-patient placebo-controlled study demonstrated that EB613 met all biomarkers and bone mineral density (BMD) endpoints with no significant safety concerns for women experiencing postmenopausal osteoporosis. Notably:</p>
        <ul>
            <li>EB613 led to rapid dose-dependent increases in bone formation markers and reductions in bone resorption markers.</li>
            <li>Improvements in lumbar spine, total hip, and femoral neck BMD were observed.</li>
            <li>The effects on trabecular and cortical bone using 3D-DXA showed significant enhancements compared to the placebo group.</li>
        </ul>
        <p>In March 2026, Entera submitted a clinical amendment to the FDA, presenting its detailed Phase 3 protocol and statistical analysis plan for EB613 under IND 505(b)(2).</p>
    </section>

    <section>
        <h3>About Entera Bio</h3>
        <p>Entera is a clinical-stage company dedicated to the development of oral peptide and protein replacement therapies aimed at addressing significant unmet medical needs. Utilizing a proprietary technology platform, N-Tab®, Entera’s pipeline includes several innovative oral peptide programs, including the oral anabolic candidate, EB613, for osteoporosis. Another notable candidate under development is EB612, an oral formulation for hypoparathyroidism.</p>
    </section>

    <section>
        <h3>Forward-Looking Statements</h3>
        <p>This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The statements reflect the company’s current expectations regarding future events and include inherent risks and uncertainties. Factors that could cause actual results to differ materially include changes in clinical data interpretation, trial outcomes, and FDA review processes.</p>
    </section>
</article>

Entera Bio Ltd. will host a webinar on April 20, 2026, featuring its lead candidate EB613 for osteoporosis. The event aims to discuss treatment opportunities and advances in oral therapies, likely influencing investor sentiment and market activity based on clinical advancements and expert insights.

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Industry News

Related News